JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 313K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lillie, S.H.
Right arrow Articles by Brown, S.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lillie, S.H.
Right arrow Articles by Brown, S.S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/1998//873 $5.00
The Journal of Cell Biology, Volume 140, Number 4, , 1998 873-883


Article

Smy1p, a Kinesin-related Protein That Does Not Require Microtubules



S.H. Lillie and S.S. Brown

Department of Anatomy and Cell Biology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0616

Abstract. We have previously reported that a defect in Myo2p, a myosin in budding yeast (Saccharomyces cerevisiae), can be partially corrected by overexpression of Smy1p, which is by sequence a kinesin-related protein (Lillie, S.H., and S.S. Brown. 1992. Nature. 356:358– 361). Such a functional link between putative actin- and microtubule-based motors is surprising, so here we have tested the prediction that Smy1p indeed acts as a microtubule-based motor. Unexpectedly, we found that abolition of microtubules by nocodazole does not interfere with the ability of Smy1p to correct the mutant Myo2p defect, nor does it interfere with the ability of Smy1p to localize properly. In addition, other perturbations of microtubules, such as treatment with benomyl or introduction of tubulin mutations, do not exacerbate the Myo2p defect. Furthermore, a mutation in SMY1 strongly predicted to destroy motor activity does not destroy Smy1p function. We have also observed a genetic interaction between SMY1 and two of the late SEC mutations, sec2 and sec4. This indicates that Smy1p can play a role even when Myo2p is wild type, and that Smy1p acts at a specific step of the late secretory pathway. We conclude that Smy1p does not act as a microtubule-based motor to localize properly or to compensate for defective Myo2p, but that it must instead act in some novel way.


We thank C. Schmidt (University of Michigan, Ann Arbor, MI) for in vitro motility assays; T. Huffaker for the gifts of benomyl and tub2 mutants, and for advice on the use of benomyl; A. Hoyt for tub1 and tub3 mutants; A. Hoyt and T. Stearns for advice on nocodazole; and B. Fuller (University of Michigan) for critical reading of the manuscript.

This work was supported by a grant to S.S. Brown, (RO1GM46745) and partially by a grant to the General Clinical Research Center at the University of Michigan (M01RR00042), both from the National Institutes of Health.

Address all correspondence to Susan S. Brown, Department of Anatomy and Cell Biology, University of Michigan Medical School, Ann Arbor, MI 48109-0616. Tel.: (313) 764-2520. Fax: (313) 763-1166. E-mail: susanbb{at}umich.edu

1. Abbreviations used in this paper: YM-P, yeast medium-Pringle; YPD, yeast extract/peptone/dextrose medium.



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents